Ossium Health's Participation at the ASH Annual Meeting
Ossium Health, a pioneering clinical-stage bioengineering company, is excited to announce its presence at the American Society of Hematology (ASH) Annual Meeting and Exposition. The event is set to occur from December 7 to December 10, 2024. Attendees can find Ossium Health at booth #217, which will be showcasing their latest advances in the field of hematologic health.
What to Expect at the Booth
Visitors to the Ossium Health booth will have the opportunity to learn about several key projects and initiatives. The company’s innovative solutions aim to enhance patient outcomes through the use of organ donor bone marrow. Ossium Health is committed to advancing the understanding and accessibility of stem cell therapies.
Key Clinical Trial Highlights
One of the major highlights at the booth will include information about the PRESERVE I Clinical Trial. This ongoing research is focused on evaluating the efficacy of Ossium’s organ donor bone marrow in treating patients with various hematologic malignancies. Currently, the trial is actively seeking participants, emphasizing its importance in advancing medical treatments in this field.
Highlighting the HOPE Program
In addition to the clinical trial, Ossium Health is also proud to present its HOPE Program. This expanded access initiative is designed specifically for patients who are unable to enroll in the PRESERVE I Clinical Trial. It showcases Ossium’s dedication to providing care and treatment to a broader spectrum of patients, ensuring that more individuals can benefit from their innovative therapies.
Across the Organization
To date, Ossium’s efforts have successfully treated three patients using their advanced bone marrow therapies. These promising outcomes highlight the significant impact that Ossium Health's research can have on patient care. The organization is focused on harnessing the power of organ donor bone marrow to create life-saving treatments for those in need, particularly for patients with life-threatening conditions.
About Ossium Health
Founded in 2016, Ossium Health is led by a team of experts dedicated to bioengineering solutions for patients facing severe health challenges, including complex hematologic conditions and organ rejection issues. The organization prioritizes innovation, leading to the development of its proprietary organ donor bone marrow banking platform, an essential resource for creating effective stem cell therapies. Ossium's manufacturing facility is FDA-registered, ensuring that their processes meet rigorous safety and quality standards.
Get Connected
For those interested in learning more about Ossium Health and its groundbreaking work, they are invited to visit the company's official website. Further engagement can also be established through their social media profiles on platforms like LinkedIn and X, where they share updates and insights regarding their developmental journey and advancements in bioengineering.
Frequently Asked Questions
What is Ossium Health?
Ossium Health is a clinical-stage bioengineering company focused on developing innovative stem cell therapies using organ donor bone marrow.
Where is Ossium Health exhibiting during the ASH 2024?
Ossium Health will be at booth #217 at the ASH Annual Meeting and Exposition in December 2024.
What is the PRESERVE I Clinical Trial?
The PRESERVE I Clinical Trial is actively recruiting participants to evaluate the effectiveness of Ossium's organ donor bone marrow for patients with hematologic malignancies.
What is the HOPE Program?
The HOPE Program is an expanded access initiative for patients who cannot participate in the PRESERVE I Clinical Trial, providing them with treatment options.
How successful has Ossium Health been with its treatments?
Ossium Health has successfully treated three patients using their bone marrow therapies, showcasing the effectiveness of their innovative approaches.
